New drug combo shows promise for tough lung cancer
NCT ID NCT04607954
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study tests whether combining durvalumab (an immunotherapy) with lurbinectedin (a chemotherapy drug) can help control advanced small cell lung cancer that has come back after prior treatment. About 29 adults whose cancer returned or didn't respond to standard chemo and immunotherapy will receive the two drugs together. The goal is to see if this combination can slow tumor growth and help patients live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT LUNG SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.